ALRN vs. EQ, EGRX, KRON, KZR, CKPT, CARM, AEON, MURA, CALC, and MNOV
Should you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include Equillium (EQ), Eagle Pharmaceuticals (EGRX), Kronos Bio (KRON), Kezar Life Sciences (KZR), Checkpoint Therapeutics (CKPT), Carisma Therapeutics (CARM), AEON Biopharma (AEON), Mural Oncology (MURA), CalciMedica (CALC), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry.
Aileron Therapeutics (NASDAQ:ALRN) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Aileron Therapeutics has a net margin of 0.00% compared to Equillium's net margin of -32.01%. Equillium's return on equity of -51.20% beat Aileron Therapeutics' return on equity.
Aileron Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
Aileron Therapeutics received 179 more outperform votes than Equillium when rated by MarketBeat users. However, 82.50% of users gave Equillium an outperform vote while only 66.88% of users gave Aileron Therapeutics an outperform vote.
Equillium has higher revenue and earnings than Aileron Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aileron Therapeutics had 5 more articles in the media than Equillium. MarketBeat recorded 9 mentions for Aileron Therapeutics and 4 mentions for Equillium. Aileron Therapeutics' average media sentiment score of 0.83 beat Equillium's score of 0.76 indicating that Aileron Therapeutics is being referred to more favorably in the media.
90.9% of Aileron Therapeutics shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 5.6% of Aileron Therapeutics shares are owned by insiders. Comparatively, 30.3% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aileron Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 393.51%. Equillium has a consensus target price of $3.90, indicating a potential upside of 153.25%. Given Aileron Therapeutics' higher probable upside, equities analysts plainly believe Aileron Therapeutics is more favorable than Equillium.
Summary
Aileron Therapeutics and Equillium tied by winning 8 of the 16 factors compared between the two stocks.
Get Aileron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aileron Therapeutics Competitors List
Related Companies and Tools
